Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Cash & Equivalents	199.74	224.65	99.19	102.99	100.71	184.43
Short-Term Investments	714.97	692.82	578.28	292.74	268.39	183.36
Cash & Short-Term Investments	914.71	917.47	677.46	395.73	369.1	367.79
Cash Growth	66.06%	35.43%	71.19%	7.22%	0.36%	16.58%
Receivables	218.87	6.82	-	-	1.41	10.26
Prepaid Expenses	16.05	10.93	9.54	8.81	7.29	4.36
Restricted Cash	1.9	1.9	3.5	7.9	7.3	-
Other Current Assets	22.86	13.52	4.97	4.03	20.2	2.19
Total Current Assets	1,174	950.64	695.47	416.47	405.3	384.6
Property, Plant & Equipment	421.95	426.41	431.29	335.56	168.59	66.02
Long-Term Investments	-	-	-	-	105.87	245.6
Other Intangible Assets	6.44	6.86	8.56	10.26	11.96	13.66
Other Long-Term Assets	1.41	1.39	4.48	3.26	0.22	0.27
Total Assets	1,604	1,385	1,140	765.55	691.94	710.15
Accounts Payable	32.94	17.67	11.39	35.87	2.87	9.46
Accrued Expenses	92.78	96.24	80.8	43.68	59.11	23.77
Short-Term Debt	10.4	10.3	-	-	-	-
Current Portion of Long-Term Debt	40	40	-	-	-	-
Current Portion of Leases	7.53	7.29	6.34	10.56	2.78	2.25
Current Income Taxes Payable	10.89	20.8	-	-	-	-
Current Unearned Revenue	111.93	2.4	-	0.87	74.1	111.06
Other Current Liabilities	40.95	0.79	4.64	14.48	-	-
Total Current Liabilities	347.43	195.49	103.17	105.46	138.85	146.54
Long-Term Debt	538.11	582.28	734.54	268.33	-	-
Long-Term Leases	102.13	104.11	111.03	104.61	78.8	23.3
Long-Term Unearned Revenue	53.83	-	-	-	55.95	131.5
Total Liabilities	1,041	881.88	948.74	478.39	273.6	301.33
Common Stock	0.23	0.23	0.22	0.2	0.2	0.2
Additional Paid-In Capital	2,211	2,140	1,806	1,300	1,219	1,053
Retained Earnings	-1,596	-1,627	-1,626	-1,026	-820.76	-644.69
Treasury Stock	-53.19	-53.19	-	-	-	-
Comprehensive Income & Other	6.7	6.44	4.75	-3.22	-0.14	-0.07
Total Common Equity	568.42	466.05	185.44	271.34	398.52	408.82
Minority Interest	-5.73	37.36	5.62	15.82	19.82	-
Shareholders' Equity	562.7	503.42	191.06	287.16	418.34	408.82
Total Liabilities & Equity	1,604	1,385	1,140	765.55	691.94	710.15
Total Debt	698.16	743.98	851.91	383.5	81.58	25.55
Net Cash (Debt)	216.55	173.49	-174.45	12.23	287.52	342.24
Net Cash Growth	-	-	-	-95.75%	-15.99%	16.27%
Net Cash Per Share	1.57	1.30	-1.46	0.11	2.73	3.30
Filing Date Shares Outstanding	140.03	135.81	124.43	107.43	106.01	104.53
Total Common Shares Outstanding	137.39	135.7	124.38	107.31	105.96	104.33
Working Capital	826.96	755.15	592.3	311.02	266.45	238.06
Book Value Per Share	4.14	3.43	1.49	2.53	3.76	3.92
Tangible Book Value	561.99	459.19	176.88	261.08	386.56	395.16
Tangible Book Value Per Share	4.09	3.38	1.42	2.43	3.65	3.79
Land	3	3	3	3	3	-
Buildings	252.53	251.32	75.99	-	-	-
Machinery	91.18	88	71.93	58.75	40.47	29.67
Construction In Progress	13.59	15.94	188.73	166.66	56.37	0.35
Leasehold Improvements	104.43	104.43	104.41	103.81	42.02	41.52

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q